Myositis induced by toripalimab
10.3760/cma.j.cn114015-20230920-00694
- VernacularTitle:特瑞普利单抗致肌炎
- Author:
Xiujuan YAN
1
;
Guangjie ZHOU
1
;
Jinfeng LI
1
Author Information
1. 山东大学附属威海市立医院药剂科，威海 264200
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Immune checkpoint inhibitors;
Myositis;
Immune-related adverse events;
Toripalimab
- From:
Adverse Drug Reactions Journal
2024;26(8):501-503
- CountryChina
- Language:Chinese
-
Abstract:
A 51-year-old female patient with ovarian cancer was treated with 5 cycles of immunotherapy, targeted therapy, and chemotherapy (pablizumab+bevacizumab+irinotecan+cisplatin), and her disease condition was stable. After that, pabolizumab was changed to toripalimab for 2 cycles because of personal reason. Two days after the last treatments, the patient developed erythema with pruritus, and eyelid edema; 10 days later, symptoms such as dysphagia, dysarthria, and decreased muscle strength appeared. Laboratory tests showed creatine kinase 2 633 U/L, interleukin-6 48.69 ng/L, positive anti-TIF1-γ antibody. Magnetic resonance imaging of limb muscles showed myositis. Electromyography showed myogenic injury of the left deltoid and tibialis anterior muscles. It was considered that the myositis was caused by toripalimab. After 16 days of treatments with methylprednisolone, intravenous human immunoglobulin for intravenous injection, and tocilizumab, the patient′s systemic erythema and eyelid edema basically subsided, the muscle zymogram continued to decline, but dysphagia and dysarthria still existed.
